Medical Developments International (MVP) H1 2025 earnings summary

Executive summary

• Group revenue increased 33% year-over-year to $20.0 million, driven by strong growth in both Pain Management and Respiratory segments.

• Underlying EBIT improved by $8.0 million to $0.2 million, reversing a prior period loss.

• Net profit after tax was $0.3 million, a turnaround from a $10.9 million loss in the prior period.

• Free cash flow improved by $6.8 million, with a closing cash balance of $17.6 million.

• Strategic priorities advanced, including margin improvement, Penthrox penetration in Australia, global expansion, and respiratory franchise growth.

Financial highlights

• Pain Management revenue rose 37% to $13.1 million, with European revenue up 83% and Australian revenue up 25%.

• Respiratory revenue increased 26% to $6.9 million, with US revenue up 23% and Australian revenue up 25%.

• Underlying EBITDA was $1.8 million, up from a $6.3 million loss in the prior period.

• Margin improvements of $2.6 million from enhanced pricing, with $3.5 million annual benefits expected.

• Operating cost reductions of $4 million achieved through efficiencies.

Outlook and guidance

• Full-year underlying EBIT for FY25 expected to be strongly improved on FY24, mainly from higher Penthrox prices and operational efficiencies.

• H2 earnings expected to be lower than H1 due to phasing of deliveries and less favorable FX movements.

• Positive operating cash flow is anticipated for the second half of FY25.